U
AGRX

UBS’s Agile Therapeutics AGRX Stock Holding History

UBS’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$8K Buy
+1
New +$15.4K ﹤0.01% 9077
2014
Q2 		– Hold
0
– – – 10261

Other funds holding AGRX

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

UBS's AGRX Position: Q3 2014 in Review

UBS opened a new position in Agile Therapeutics (AGRX) in Q3 2014: 1 share worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #9077 among its holdings.

19 funds tracked by Wall St. Rank hold AGRX as of Q3 2014.

  • UBS held 1 share of Agile Therapeutics worth $8K as of Q3 2014.
  • Agile Therapeutics was a new UBS position in Q3 2014.
  • Agile Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9077 holding.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.